Target intelligence / Profile preview

Solute carrier family 26 member 3 (SLC26A3) (SLC26A3)

Target
SLC26A3
Molecular classification
Transporter, Solute carrier family, Anion exchanger
01

Overview

Solute carrier family 26 member 3 (SLC26A3), commonly referred to as Down-Regulated in Adenoma (DRA), is a vital transmembrane transporter located on the apical membrane of intestinal epithelial cells, specifically in the ileum and colon (UniProt P40879). It facilitates the exchange of luminal chloride for intracellular bicarbonate or hydroxide, serving as the primary mechanism for intestinal chloride absorption (PubMed: 28611103). Loss-of-function mutations in SLC26A3 lead to congenital chloride diarrhea (CLD), a condition marked by severe electrolyte loss and dehydration (PubMed: 8944020). In therapeutic development, SLC26A3 is targeted by novel small-molecule inhibitors like DRAinh-A270 to treat chronic constipation by blocking chloride uptake, which increases luminal osmolarity and promotes water retention in the gut (PubMed: 30655315). Additionally, its role in sodium-independent chloride absorption makes it a potential target for managing hypertension and fluid overload (PubMed: 26912540). Reduced expression of SLC26A3 is also a hallmark of inflammatory bowel disease (IBD), where it contributes to the pathogenesis of diarrhea (PubMed: 25113822).

Other names
Down-regulated in adenomaDRAChloride anion exchangerCLDSolute carrier family 26 member 3
02

Mechanism of action

Inhibition of the SLC26A3-mediated chloride/bicarbonate exchange to reduce intestinal fluid absorption and increase stool water content.

03

Biological functions

Chloride/bicarbonate exchangeIntestinal fluid absorptionElectrolyte homeostasispH regulation
04

Disease associations

Congenital chloride diarrheaInflammatory bowel diseaseUlcerative colitisConstipationHypertensionNephrolithiasis
05

Safety considerations

Metabolic alkalosisDehydrationHypochloremiaElectrolyte imbalancePotential exacerbation of intestinal inflammation
06

Interacting drugs

DRAinh-A270

3 more in the full profile.

07

Biomarkers

Fecal chloride concentrationSLC26A3 mRNA expression levelsSLC26A3 protein expression in colonic biopsiesGenetic mutations in SLC26A3 gene

Beyond the preview

Go deeper on Solute carrier family 26 member 3 (SLC26A3) (SLC26A3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 26 member 3 (SLC26A3) (SLC26A3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call